A pharmacokinetic/pharmacodynamic approach to predict the cumulative cortisol suppression of inhaled corticosteroids

Bernd Meibohm, Günther Hochhaus, Helmut Möllmann, Jürgen Barth, Melanie Wagner, Michael Krieg, Ricarda Stöckmann, Hartmut Derendorf

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

The suppression of endogenous cortisol release is one of the major systemic side effects of inhaled corticosteroids in the treatment of asthma. The circadian rhythm of the endogenous cortisol release and the resulting plasma concentrations as well as the release suppression during corticosteroid therapy could previously be described with an integrated PK/PD model. Based on this model, a PK/PD approach was developed to quantify and predict the cumulative cortisol suppression (CCS) as a surrogate marker for the systemic activity of inhaled corticosteroid therapy. The presented method was applied to predict CCS after single doses and during short-term multiple dosing of the inhaled corticosteroids flunisolide (FLU), fluticasone propionate (FP), and triamcinolone acetonide (TCA), and after oral methylprednisolone as systemic reference therapy. Drug-specific PK and PD parameters were obtained from previous single-dose studies and extrapolated to the multiple-dose situation. For single dosing, a similar CCS within the range of 16-21% was predicted for FP 250 μg, FLU 500 μg, and TCA 1000 μg. For multiple dosing, a respective CCS of 28-33% was calculated for FLU 500 μg bid, FP 250 μg, bid, and TCA 1000 μg bid. Higher cortisol suppression compared to these single and multiple dosing regimens of the inhaled corticosteroids was predicted after oral doses of only 1 mg and 2 mg methylprednisolone, respectively. The predictive power of the approach was evaluated by comparing the PK/PD-based simulations with data reported previously in clinical studies. The predicted CCS values were in good correlation with the clinically observed results. Hence, the presented PK/PD approach allows valid predictions of CCS for single and short-term multiple dosing of inhaled corticosteroids and facilitates comparisons between different dosing regimens and steroids.

Original languageEnglish (US)
Pages (from-to)127-147
Number of pages21
JournalJournal of Pharmacokinetics and Biopharmaceutics
Volume27
Issue number2
DOIs
StatePublished - Oct 26 1999

Fingerprint

Hydrocortisone
Adrenal Cortex Hormones
flunisolide
Pharmacokinetics
Triamcinolone Acetonide
Methylprednisolone
Circadian Rhythm
Therapeutics
Asthma
Biomarkers
Steroids
Pharmaceutical Preparations
Fluticasone

All Science Journal Classification (ASJC) codes

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology (medical)

Cite this

A pharmacokinetic/pharmacodynamic approach to predict the cumulative cortisol suppression of inhaled corticosteroids. / Meibohm, Bernd; Hochhaus, Günther; Möllmann, Helmut; Barth, Jürgen; Wagner, Melanie; Krieg, Michael; Stöckmann, Ricarda; Derendorf, Hartmut.

In: Journal of Pharmacokinetics and Biopharmaceutics, Vol. 27, No. 2, 26.10.1999, p. 127-147.

Research output: Contribution to journalArticle

Meibohm, Bernd ; Hochhaus, Günther ; Möllmann, Helmut ; Barth, Jürgen ; Wagner, Melanie ; Krieg, Michael ; Stöckmann, Ricarda ; Derendorf, Hartmut. / A pharmacokinetic/pharmacodynamic approach to predict the cumulative cortisol suppression of inhaled corticosteroids. In: Journal of Pharmacokinetics and Biopharmaceutics. 1999 ; Vol. 27, No. 2. pp. 127-147.
@article{09609e23a5cd4beea5b8ae6b539260f3,
title = "A pharmacokinetic/pharmacodynamic approach to predict the cumulative cortisol suppression of inhaled corticosteroids",
abstract = "The suppression of endogenous cortisol release is one of the major systemic side effects of inhaled corticosteroids in the treatment of asthma. The circadian rhythm of the endogenous cortisol release and the resulting plasma concentrations as well as the release suppression during corticosteroid therapy could previously be described with an integrated PK/PD model. Based on this model, a PK/PD approach was developed to quantify and predict the cumulative cortisol suppression (CCS) as a surrogate marker for the systemic activity of inhaled corticosteroid therapy. The presented method was applied to predict CCS after single doses and during short-term multiple dosing of the inhaled corticosteroids flunisolide (FLU), fluticasone propionate (FP), and triamcinolone acetonide (TCA), and after oral methylprednisolone as systemic reference therapy. Drug-specific PK and PD parameters were obtained from previous single-dose studies and extrapolated to the multiple-dose situation. For single dosing, a similar CCS within the range of 16-21{\%} was predicted for FP 250 μg, FLU 500 μg, and TCA 1000 μg. For multiple dosing, a respective CCS of 28-33{\%} was calculated for FLU 500 μg bid, FP 250 μg, bid, and TCA 1000 μg bid. Higher cortisol suppression compared to these single and multiple dosing regimens of the inhaled corticosteroids was predicted after oral doses of only 1 mg and 2 mg methylprednisolone, respectively. The predictive power of the approach was evaluated by comparing the PK/PD-based simulations with data reported previously in clinical studies. The predicted CCS values were in good correlation with the clinically observed results. Hence, the presented PK/PD approach allows valid predictions of CCS for single and short-term multiple dosing of inhaled corticosteroids and facilitates comparisons between different dosing regimens and steroids.",
author = "Bernd Meibohm and G{\"u}nther Hochhaus and Helmut M{\"o}llmann and J{\"u}rgen Barth and Melanie Wagner and Michael Krieg and Ricarda St{\"o}ckmann and Hartmut Derendorf",
year = "1999",
month = "10",
day = "26",
doi = "10.1023/A:1020670421957",
language = "English (US)",
volume = "27",
pages = "127--147",
journal = "Journal of Pharmacokinetics and Pharmacodynamics",
issn = "1567-567X",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - A pharmacokinetic/pharmacodynamic approach to predict the cumulative cortisol suppression of inhaled corticosteroids

AU - Meibohm, Bernd

AU - Hochhaus, Günther

AU - Möllmann, Helmut

AU - Barth, Jürgen

AU - Wagner, Melanie

AU - Krieg, Michael

AU - Stöckmann, Ricarda

AU - Derendorf, Hartmut

PY - 1999/10/26

Y1 - 1999/10/26

N2 - The suppression of endogenous cortisol release is one of the major systemic side effects of inhaled corticosteroids in the treatment of asthma. The circadian rhythm of the endogenous cortisol release and the resulting plasma concentrations as well as the release suppression during corticosteroid therapy could previously be described with an integrated PK/PD model. Based on this model, a PK/PD approach was developed to quantify and predict the cumulative cortisol suppression (CCS) as a surrogate marker for the systemic activity of inhaled corticosteroid therapy. The presented method was applied to predict CCS after single doses and during short-term multiple dosing of the inhaled corticosteroids flunisolide (FLU), fluticasone propionate (FP), and triamcinolone acetonide (TCA), and after oral methylprednisolone as systemic reference therapy. Drug-specific PK and PD parameters were obtained from previous single-dose studies and extrapolated to the multiple-dose situation. For single dosing, a similar CCS within the range of 16-21% was predicted for FP 250 μg, FLU 500 μg, and TCA 1000 μg. For multiple dosing, a respective CCS of 28-33% was calculated for FLU 500 μg bid, FP 250 μg, bid, and TCA 1000 μg bid. Higher cortisol suppression compared to these single and multiple dosing regimens of the inhaled corticosteroids was predicted after oral doses of only 1 mg and 2 mg methylprednisolone, respectively. The predictive power of the approach was evaluated by comparing the PK/PD-based simulations with data reported previously in clinical studies. The predicted CCS values were in good correlation with the clinically observed results. Hence, the presented PK/PD approach allows valid predictions of CCS for single and short-term multiple dosing of inhaled corticosteroids and facilitates comparisons between different dosing regimens and steroids.

AB - The suppression of endogenous cortisol release is one of the major systemic side effects of inhaled corticosteroids in the treatment of asthma. The circadian rhythm of the endogenous cortisol release and the resulting plasma concentrations as well as the release suppression during corticosteroid therapy could previously be described with an integrated PK/PD model. Based on this model, a PK/PD approach was developed to quantify and predict the cumulative cortisol suppression (CCS) as a surrogate marker for the systemic activity of inhaled corticosteroid therapy. The presented method was applied to predict CCS after single doses and during short-term multiple dosing of the inhaled corticosteroids flunisolide (FLU), fluticasone propionate (FP), and triamcinolone acetonide (TCA), and after oral methylprednisolone as systemic reference therapy. Drug-specific PK and PD parameters were obtained from previous single-dose studies and extrapolated to the multiple-dose situation. For single dosing, a similar CCS within the range of 16-21% was predicted for FP 250 μg, FLU 500 μg, and TCA 1000 μg. For multiple dosing, a respective CCS of 28-33% was calculated for FLU 500 μg bid, FP 250 μg, bid, and TCA 1000 μg bid. Higher cortisol suppression compared to these single and multiple dosing regimens of the inhaled corticosteroids was predicted after oral doses of only 1 mg and 2 mg methylprednisolone, respectively. The predictive power of the approach was evaluated by comparing the PK/PD-based simulations with data reported previously in clinical studies. The predicted CCS values were in good correlation with the clinically observed results. Hence, the presented PK/PD approach allows valid predictions of CCS for single and short-term multiple dosing of inhaled corticosteroids and facilitates comparisons between different dosing regimens and steroids.

UR - http://www.scopus.com/inward/record.url?scp=0032822407&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032822407&partnerID=8YFLogxK

U2 - 10.1023/A:1020670421957

DO - 10.1023/A:1020670421957

M3 - Article

VL - 27

SP - 127

EP - 147

JO - Journal of Pharmacokinetics and Pharmacodynamics

JF - Journal of Pharmacokinetics and Pharmacodynamics

SN - 1567-567X

IS - 2

ER -